Literature DB >> 28827411

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Srdan Verstovsek1, Francesco Passamonti2, Alessandro Rambaldi3,4, Giovanni Barosi5, Elisa Rumi6,7, Elisabetta Gattoni8, Lisa Pieri9,10, Huiling Zhen11, Muriel Granier11, Albert Assad11, Mario Cazzola6,7, Hagop M Kantarjian1, Tiziano Barbui12, Alessandro M Vannucchi9,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28827411      PMCID： PMC5639482          DOI： 10.1182/blood-2017-02-765032

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

Review 1.  Genetic and epigenetic complexity in myeloproliferative neoplasms.

Authors:  Nicholas C P Cross
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Authors:  Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

6.  Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.

Authors:  Juan-Carlos Hernández-Boluda; Alberto Alvarez-Larrán; Montse Gómez; Anna Angona; Paula Amat; Beatriz Bellosillo; Luz Martínez-Avilés; Blanca Navarro; Anabel Teruel; Francisco Martínez-Ruiz; Carles Besses
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

7.  Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Authors:  Francesco Passamonti; Martin Griesshammer; Francesca Palandri; Miklos Egyed; Giulia Benevolo; Timothy Devos; Jeannie Callum; Alessandro M Vannucchi; Serdar Sivgin; Caroline Bensasson; Mahmudul Khan; Nadjat Mounedji; Guray Saydam
Journal:  Lancet Oncol       Date:  2016-12-02       Impact factor: 41.316

8.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

Review 9.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 10.  Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.

Authors:  A Tefferi; T Barbui
Journal:  Leukemia       Date:  2013-04-05       Impact factor: 11.528
View more
  19 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 2.  Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Loretta Nastoupil; Megan Dupuis; Lisa Zhou; Sherry Pierce; Keyur P Patel; Lucia Masarova; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

Review 3.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 4.  What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Authors:  Alessandro M Vannucchi; Paola Guglielmelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Janus kinase inhibition and symptom control in myeloproliferative neoplasms.

Authors:  Prithviraj Bose; Mahesh Swaminathan
Journal:  Curr Med Res Opin       Date:  2018-03-12       Impact factor: 2.580

Review 6.  The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.

Authors:  Marie Strickland; Lynn Quek; Bethan Psaila
Journal:  Br J Haematol       Date:  2021-10-07       Impact factor: 8.615

Review 7.  Emerging agents and regimens for polycythemia vera and essential thrombocythemia.

Authors:  Rory M Shallis; Nikolai A Podoltsev
Journal:  Biomark Res       Date:  2021-05-28

Review 8.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

9.  Ruxolitinib for essential thrombocythemia?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Oncoscience       Date:  2017-11-01

Review 10.  JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Authors:  William Vainchenker; Emilie Leroy; Laure Gilles; Caroline Marty; Isabelle Plo; Stefan N Constantinescu
Journal:  F1000Res       Date:  2018-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.